EUVIMEDEUVIMED entdecken
Crossref

Tumour‐infiltrating lymphocytes, tertiary lymphoid structures and myxoid stroma predict upstaging of ductal carcinoma in situ in breast biopsies

Chung-Yen Huang iD, Yu-Jui Wang iD, Min-Shu Hsieh iD, Pin-Yu Lin iD, Yi-Hsuan Lee iD

Histopathology · 2026

DOI: 10.1111/his.70009 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Histopathology, 2026. Verfasst von Chung-Yen Huang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, National Taiwan University Hospital, Taipei, Taiwan. Hauptthemen laut MEDLINE: Lymphocytes, Tumor-Infiltrating, Breast Neoplasms, Carcinoma, Intraductal, Noninfiltrating, Tertiary Lymphoid Structures. Die Arbeit nennt 39 Literaturangaben. Gefördert von: National Science and Technology Council, Taiwan.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

We aimed to evaluate tumour‐infiltrating lymphocytes (TILs), tertiary lymphoid structures (TLSs) and myxoid stroma in breast biopsies diagnosed with atypical ductal hyperplasia (ADH) and ductal carcinoma in situ (DCIS). We hypothesized that these stromal features may help identify patients at high risk for upstaging to invasive carcinoma. Methods and results Analysis included 592 patients diagnosed with ADH or DCIS via breast biopsy. TILs, TLSs and myxoid stroma were correlated with high‐risk features, including larger lesion size, higher BIRADS scores, higher nuclear grade, comedonecrosis, oestrogen receptor (ER) negativity and HER2 overexpression, and were associated with an increased risk of upstaging. In a multivariate logistic regression model incorporating stromal TILs or TLSs, myxoid stroma and basic pathological factors, both stromal TILs or TLSs and myxoid stroma showed independent predictive value, with an AUC of 0.77. The AUC further increased to 0.87 when clinical factors and immunohistochemistry (ER and HER2) were included. Both stromal TILs or TLSs and myxoid stroma demonstrated predictive power exceeding that of comedonecrosis and comparable with nuclear grade. The two pathologists showed moderate to high interobserver agreement in evaluating these stromal and immune features. A simplified scoring system based on six clinicopathological variables retained strong discriminative ability (AUC 0.84).

Conclusions

Stromal TILs, TLSs and myxoid stroma are robust predictors of upstaging to invasive carcinoma in patients diagnosed with ADH/DCIS on biopsy. These features can be readily assessed by pathologists using only H&E staining and should be considered in future risk stratification models to inform clinical decision‐making.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lymphocytes, Tumor-InfiltratingBreast NeoplasmsCarcinoma, Intraductal, NoninfiltratingTertiary Lymphoid StructuresHumansFemaleMiddle AgedAgedAdultNeoplasm StagingStromal CellsBiopsyAged, 80 and overBreast

Autor:innen und Institutionen

  • Department of Pathology, National Taiwan University Hospital, Taipei, Taiwan.
  • Department of Laboratory Medicine, National Taiwan University Hospital, Taipei, Taiwan.
  • Department of Pathology, National Taiwan University Cancer Center, Taipei, Taiwan.

ORCID-Profile: Chung-Yen Huang, Yu-Jui Wang, Min-Shu Hsieh, Pin-Yu Lin, Yi-Hsuan Lee

Förderung

  • National Science and Technology Council, Taiwan

Zitieren

APA

Huang, C. Y., Wang, Y. J., Hsieh, M. S., Lin, P. Y., & Lee, Y. H. (2026). Tumour‐infiltrating lymphocytes, tertiary lymphoid structures and myxoid stroma predict upstaging of ductal carcinoma in situ in breast biopsies. Histopathology. https://doi.org/10.1111/his.70009

Vancouver

Huang CY, Wang YJ, Hsieh MS, Lin PY, Lee YH. Tumour‐infiltrating lymphocytes, tertiary lymphoid structures and myxoid stroma predict upstaging of ductal carcinoma in situ in breast biopsies. Histopathology. 2026. doi:10.1111/his.70009

BibTeX
@article{Huang2026,
  author = {Huang, Chung-Yen and Wang, Yu-Jui and Hsieh, Min-Shu and Lin, Pin-Yu and Lee, Yi-Hsuan},
  title = {Tumour‐infiltrating lymphocytes, tertiary lymphoid structures and myxoid stroma predict upstaging of ductal carcinoma in situ in breast biopsies},
  journal = {Histopathology},
  year = {2026},
  doi = {10.1111/his.70009}
}
Kostenlos starten →